Plain-English translation of NCT07304856 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying tiny particles called extracellular vesicles that float in the blood. These particles may act as biological signals that tell doctors how LAM (a rare lung disease) is affecting the lungs. This study will compare these particles in people with LAM, people with a related genetic condition, and healthy people to see if the particles could help doctors monitor the disease.
LAM is a rare lung disease that can be difficult to monitor because standard tests don't always show how the disease is progressing. Scientists believe that tiny particles in the blood could serve as early warning signals, helping doctors catch disease changes sooner and potentially improve patient care.
You likely qualify if…
You likely don't qualify if…
You will visit the lung clinic during your regular appointments. At these visits, the research team will collect a blood sample, review your medical records, and gather information about how your lungs are functioning. The blood sample will be processed in a lab to isolate and analyze the tiny particles, which will then be compared with your health information to see if these particles reflect your disease status.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
Italy
Sponsor
University of Milan
Enrollment target
~80 participants
Started
April 2025
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Sex
Female only
Last updated on clinicaltrials.gov in December 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.